Do you like getting the inside scoop on your favorite companies? One idea on how to get an inside peek is by considering insider buying. Company insiders report when they buy company stock, and this is viewed very positively by the market.
We ran a screen on the biotech industry for stocks seeing significant net insider purchases over the last six months, indicating company insiders at these firms are optimistic on their employer's outlooks.
Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the top six stocks mentioned below. Analyst ratings sourced from Zacks Investment Research.
Your browser does not support iframes.
We also created a price-weighted index of the stocks mentioned below, and monitored the performance of the list relative to the S&P 500 index over the last month. To access a complete analysis of this list's recent performance, click here.
Do you think these stocks are poised to move higher? Use this list as a starting point for your own analysis.
1. Agenus Inc. (AGEN): Develops and commercializes immunotherapies for cancer and infectious diseases. Over the last six months, insiders were net buyers of 2,144,705 shares, which represents about 10.79% of the company's 19.87M share float.
2. China Biologic Products, Inc. (CBPO): Engages in the research, development, manufacturing, and sale of plasma-based pharmaceutical products. Over the last six months, insiders were net buyers of 795,860 shares, which represents about 11.53% of the company's 6.90M share float.
3. Halozyme Therapeutics, Inc. (HALO): Engages in the development and commercialization of recombinant human enzymes that transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefits. Over the last six months, insiders were net buyers of 1,934,950 shares, which represents about 3% of the company's 64.53M share float.
4. Incyte Corporation (INCY): Focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and inflammatory and autoimmune diseases. Over the last six months, insiders were net buyers of 4,476,050 shares, which represents about 3.56% of the company's 125.65M share float.
5. NuPathe, Inc. (PATH): Focuses on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. Over the last six months, insiders were net buyers of 37,500 shares, which represents about 0.81% of the company's 4.65M share float.
6. QLT Inc. (QLTI): Engages in the development and commercialization of therapies for the eye. Over the last six months, insiders were net buyers of 1,655,013 shares, which represents about 5.69% of the company's 29.07M share float.
7. Seattle Genetics Inc. (SGEN): Focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. Over the last six months, insiders were net buyers of 1,147,052 shares, which represents about 1% of the company's 114.75M share float.
*Insider data sourced from Yahoo Finance, all other data sourced from Finviz.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
No comments:
Post a Comment